Method comparison of HPLC-ninhydrin-photometry and UHPLC-PITC-tandem mass spectrometry for serum amino acid analyses in patients with complex congenital heart disease and controls
Open Access
- 15 December 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Metabolomics
- Vol. 16 (12), 1-10
- https://doi.org/10.1007/s11306-020-01741-8
Abstract
Introduction Metabolomics studies are not routine when quantifying amino acids (AA) in congenital heart disease (CHD). Objectives Comparative analysis of 24 AA in serum by traditional high-performance liquid chromatography (HPLC) based on ion exchange and ninhydrin derivatisation followed by photometry (PM) with ultra-high-performance liquid chromatography and phenylisothiocyanate derivatisation followed by tandem mass spectrometry (TMS); interpretation of findings in CHD patients and controls. Methods PM: Sample analysis as above (total run time, ~ 119 min). TMS: Sample analysis by AbsoluteIDQ® p180 kit assay (BIOCRATES Life Sciences AG, Innsbruck, Austria), which employs PITC derivatisation; separation of analytes on a Waters Acquity UHPLC BEH18 C18 reversed-phase column, using water and acetonitrile with 0.1% formic acid as the mobile phases; and quantification on a Triple-Stage Quadrupole tandem mass spectrometer (Thermo Fisher Scientific, Waltham, MA) with electrospray ionisation in the presence of internal standards (total run time, ~ 8 min). Calculation of coefficients of variation (CV) (for precision), intra- and interday accuracies, limits of detection (LOD), limits of quantification (LOQ), and mean concentrations. Results Both methods yielded acceptable results with regard to precision (CV < 10% PM, < 20% TMS), accuracies (< 10% PM, < 34% TMS), LOD, and LOQ. For both Fontan patients and controls AA concentrations differed significantly between methods, but patterns yielded overall were parallel. Conclusion Serum AA concentrations differ with analytical methods but both methods are suitable for AA pattern recognition. TMS is a time-saving alternative to traditional PM under physiological conditions as well as in patients with CHD. Trial registration number ClinicalTrials.gov Identifier NCT03886935, date of registration March 27th, 2019 (retrospectively registered).Funding Information
- Tiroler Wissenschaftsförderung (UNI-0404-2126)
- University of Innsbruck and Medical University of Innsbruck
This publication has 40 references indexed in Scilit:
- Effects of smoking and smoking cessation on human serum metabolite profile: results from the KORA cohort studyBMC Medicine, 2013
- Human serum metabolic profiles are age dependentAging Cell, 2012
- A Genome-Wide Metabolic QTL Analysis in Europeans Implicates Two Loci Shaped by Recent Positive SelectionPLoS Genetics, 2011
- Differences between Human Plasma and Serum Metabolite ProfilesPLOS ONE, 2011
- Reliability of Serum Metabolite Concentrations over a 4-Month Period Using a Targeted Metabolomic ApproachPLOS ONE, 2011
- β-Elemene Piperazine Derivatives Induce Apoptosis in Human Leukemia Cells through Downregulation of c-FLIP and Generation of ROSPLOS ONE, 2011
- Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathyEuropean Journal of Clinical Investigation, 2010
- Usefulness of Natriuretic Peptide Levels to Predict Mortality in Adults With Congenital Heart DiseaseThe American Journal of Cardiology, 2010
- A genome-wide perspective of genetic variation in human metabolismNature Genetics, 2009
- Quality of analytical performance in inherited metabolic disorders: the role of ERNDIMJournal of Inherited Metabolic Disease, 2008